Extracellular vesicles in disease {#Sec1}
=================================

The Articles gathered in this Collection have unveiled a number of ways in which EVs may serve in disease identification, for instance: the EV-associated miRNA of pleural fluids and lavages provide an untapped source of biomarkers for lung cancer diagnosis^[@CR1]^; chemoresistance in colorectal cancer may be predicted through the evaluation of exosomal circRNA^[@CR2]^, or exosomal miRNAs may serve for the identification and prognosis of metastatic colorectal cancer^[@CR3]^; and a decrease in the Gelsolin content of plasma-EVs acts as a biomarker for dementia with Lewy Bodies, distinguishing these patients from those with Alzheimer's Disease^[@CR4]^.

Other Articles included in the Collection have explored the use of EVs in therapeutics. For the treatment of immune-related diseases, the application of an inflammatory stimulus is shown to improve the anti-inflammatory and/or immunosuppressive potential of EVs secreted by adipose mesenchymal stem cells^[@CR5]^. Cytoprotection of stressed cardiomyocytes through the use of EVs derived from mesenchymal stromal cells^[@CR6]^, and the prevention of glucocorticoid-induced osteoporosis -- through the suppression of osteoblasts' ferroptic pathway -- by EVs extracted from bone marrow-derived endothelial progenitor^[@CR7]^, were also demonstrated. As well as applying naturally occurring EVs, one of the published original Articles has demonstrated engineered EVs as a feasible therapeutic tool. Do *et al*. have developed a chimeric protein by fusing human lysosomal β-glucocerebrosidase (GBA) to an exosome-anchoring protein; this chimeric protein was successfully secreted into EVs, and delivered to recipient cells, providing a potential strategy for the treatment of lysosomal storage diseases^[@CR8]^.

Extracellular vesicles' biology and endogenous function {#Sec2}
=======================================================

The Collection also advances our knowledge of EVs biology and function. For example, two articles have studied the lipidome and glycans of EVs, highlighting the lipidome profile as a possible marker to discriminate exosomes from microvesicles^[@CR9]^, and identifying glycans as key players in the tuning of EV uptake through charge-based effects, direct glycan recognition or both^[@CR10]^. Other roles of EVs have also been explored, such as oviductal EVs modulating sperm function and fertilization^[@CR11]^, or EVs from aged astrocytes inhibiting the maturation of oligodendrocyte progenitor cells into oligodendrocytes^[@CR12]^. In addition, the involvement of EVs in the formation of the pre-metastatic niche^[@CR13]^, or the neuroprotective role of EVs containing Cystatin C^[@CR14]^, were also investigated.

Tools and methods for studying Extracellular Vesicles {#Sec3}
=====================================================

Given EVs size and heterogeneity, their isolation, detection and characterization still remains a challenge, although much effort is being made to improve methodological tools for EV study. A new aqueous two-phase system-based isolation protocol for EVs isolation at high efficiency and purity was reported^[@CR15]^. A further Article reported a new EV immunolabeling method that can be incorporated into existing NTA protocols to provide particle concentration, size distribution, and surface phenotype of EV samples^[@CR16]^. In addition, a luminescence-based assay for EV uptake assays -- clearly discriminating between EV uptake, and EV binding to the target cell -- has been developed^[@CR17]^. Finally, an inducible CD9-GFP mouse was generated, providing a tool that enables EV labelling in a cell-type specific manner, while simultaneously allowing *in vivo* experimentation^[@CR18]^.

Many thanks to all the contributors (authors and reviewers) to this Collection.
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